You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,039,810


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,039,810
Title:Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies
Abstract: Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
Inventor(s): Morales; Mercedes (San Francisco, CA), Imran; Mir (Los Altos Hills, CA), Korupolu; Radhika (Fremont, CA), Hashim; Mir (Fremont, CA)
Assignee: InCube Labs, LLC (San Jose, CA)
Application Number:14/714,136
Patent Claims:1. A shaped mass comprising an interleukin neutralizing antibody (AI-antibody), the shaped mass formed by compression of a precursor material comprising the AI-antibody, wherein at least about 65% of the AI-antibody in the shaped mass has affinity for an epitope on an interleukin molecule, wherein the AI-antibody is an immunoglobulin G (IgG), the shaped mass having a density in a range of about 0.80 to about 1.10 mg/mm.sup.3.

2. The shaped mass of claim 1, wherein the density is in a range of about 0.85 to about 1.05 mg/mm.sup.3.

3. The shaped mass of claim 1 wherein the density is in a range of about 1.00 to about 1.01 mg/mm.sup.3.

4. The shaped mass of claim 1, wherein the precursor material has a particle size in a range of about 100 to 400 .mu.m.

5. The shaped mass of claim 1, wherein at least about 80% of AI-antibody in the shaped mass has affinity for an epitope on an interleukin molecule.

6. The shaped mass of claim 1, wherein the AI-antibody comprises an antibody to a member of the interleukin-17 family of cytokines.

7. The shaped mass of claim 6, wherein the AI-antibody is secukinumab.

8. The shaped mass of claim 6, wherein the AI-antibody is ixekizumab.

9. The shaped mass of claim 6, wherein the AI-antibody is brodalumab.

10. The shaped mass of claim 6, wherein a dose of AI-antibody in the shaped mass is in a range from about 1 to 5 mg.

11. The shaped mass of claim 1, wherein the compression is performed in a mold or fixture.

12. The shaped mass of claim 1, wherein the shaped mass is formed by compression of a powder comprising the AI-antibody.

13. The shaped mass of claim 1, wherein the shaped mass has a pellet or cylindrical shape.

14. The shaped mass of claim 1, wherein the shaped mass has a tablet shape.

15. The shaped mass of claim 1, wherein the shaped mass is configured to penetrate and be inserted into the wall of the small intestine by the application of force.

16. The shaped mass of claim 1, wherein the shaped mass comprises a pharmaceutical excipient.

17. The shaped mass of claim 16, wherein the pharmaceutical excipient comprises at least one of a lubricant, a binding agent, a bulking agent or polyethylene glycol (PEG).

18. A shaped mass comprising an AI-antibody, the shaped mass formed by compression of a precursor material comprising the AI-antibody, wherein at least about 65% of the AI-antibody in the shaped mass has affinity for an epitope on an interleukin molecule, wherein the AI-antibody is an immunoglobulin G (IgG), and wherein the precursor material has a particle size in a range of about 50 to 450 .mu.m.

19. The shaped mass of claim 18, wherein the precursor material has a particle size in the range of 100 to 400 .mu.m.

20. The shaped mass of claim 18, wherein the shaped mass has a density in a range of about 0.80 to about 1.10 mg/mm.sup.3.

21. The shaped mass of claim 18, wherein the AI-antibody comprises an antibody to a member of the interleukin-17 family of cytokines.

22. The shaped mass of claim 21, wherein the AI-antibody is secukinumab.

23. The shaped mass of claim 21, wherein the AI-antibody is ixekizumab.

24. The shaped mass of claim 21, wherein the AI-antibody is brodalumab.

25. The shaped mass of claim 21, wherein a dose of AI-antibody in the shaped mass is in a range from about 1 to 5 mg.

Details for Patent 10,039,810

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novartis Pharmaceuticals Corporation COSENTYX secukinumab Injection 125504 01/21/2015 ⤷  Try a Trial 2034-05-15
Novartis Pharmaceuticals Corporation COSENTYX secukinumab For Injection 125504 01/21/2015 ⤷  Try a Trial 2034-05-15
Novartis Pharmaceuticals Corporation COSENTYX secukinumab Injection 125504 05/28/2021 ⤷  Try a Trial 2034-05-15
Eli Lilly And Company TALTZ ixekizumab Injection 125521 03/22/2016 ⤷  Try a Trial 2034-05-15
Octapharma Pharmazeutika Produktionsges.m.b.h. CUTAQUIG immune globulin subcutaneous (human)-hipp Solution 125668 12/12/2018 ⤷  Try a Trial 2034-05-15
Valeant Pharmaceuticals Luxembourg S.à.r.l. SILIQ brodalumab Injection 761032 02/15/2017 ⤷  Try a Trial 2034-05-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.